-
公开(公告)号：US20120149085A1
公开(公告)日：2012-06-14
申请号：US13402480
申请日：2012-02-22
Applicant: David M. GOLDENBERG , Hans J. HANSEN , Chien-Hsing Ken CHANG , Sailaja S. VANAMA , Edmund A. ROSSI
Inventor： David M. GOLDENBERG , Hans J. HANSEN , Chien-Hsing Ken CHANG , Sailaja S. VANAMA , Edmund A. ROSSI
IPC: C12N9/96
CPC classification number: C07K16/2803 , A61K47/6817 , A61K47/6877 , C07K16/2833 , C07K2317/24 , C07K2317/41 , C07K2319/00 , C07K2319/33 , C12N9/22 , C12N2510/02
Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.
Abstract translation: 可以在哺乳动物细胞培养物中产生含有与抗体或抗体片段融合的细胞毒性RNA的重组免疫毒素。 令人惊讶的是，可以制备含有与一个抗体可变结构域的N末端融合的细胞毒性RNA的免疫毒素，并保留特异性结合抗原的能力。 免疫毒素可以用于治疗与不想要的或不适当的细胞增殖或活化相关的疾病或综合征的各种治疗方法。
-
公开(公告)号：US09184781B2
公开(公告)日：2015-11-10
申请号：US12250396
申请日：2008-10-13
Applicant: Hans Hansen , Edmund Rossi , Chien-Hsing Ken Chang , David M. Goldenberg
Inventor： Hans Hansen , Edmund Rossi , Chien-Hsing Ken Chang , David M. Goldenberg
IPC: A61K39/395 , H04B1/48
CPC classification number: H04B1/48
Abstract: Humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis are disclosed. Methods of making the humanized, chimeric and human anti-CD20 antibodies are disclosed. A humanized anti-HSG (histamine-succinyl-glycyl) monoclonal antibody designated h679 which binds with high affinity to molecules containing the moiety histamine-succinyl-glycyl (HSG), and methods of making the humanized anti-HSG antibody also are disclosed.
Abstract translation: 结合人B细胞标记（称为CD20）的人源化，嵌合和人抗CD20抗体和CD20抗体融合蛋白，其可用于治疗和诊断B细胞病症，例如B细胞恶性肿瘤和自身免疫 疾病，治疗和诊断方法。 公开了制备人源化，嵌合抗体和人抗CD20抗体的方法。 公开了以高亲和力结合含有组胺 - 琥珀酰 - 甘氨酰（HSG）部分的分子结合的命名为h679的人源化抗HSG（组胺 - 琥珀酰 - 甘氨酰）单克隆抗体，以及制备人源化抗HSG抗体的方法。
-
Patent Agency Ranking
公开(公告)号：US20090240037A1
公开(公告)日：2009-09-24
申请号：US12250396
申请日：2008-10-13
Applicant: Edmund ROSSI , Chien-Hsing Ken CHANG , David M. GOLDENBERG , Hans HANSEN
Inventor： Edmund ROSSI , Chien-Hsing Ken CHANG , David M. GOLDENBERG , Hans HANSEN
IPC: C07K16/00
CPC classification number: H04B1/48
Abstract: Humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which are useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis are disclosed. Methods of making the humanized, chimeric and human anti-CD20 antibodies are disclosed. A humanized anti-HSG (histamine-succinyl-glycyl) monoclonal antibody designated h679 which binds with high affinity to molecules containing the moiety histamine-succinyl-glycyl (HSG), and methods of making the humanized anti-HSG antibody also are disclosed.
Abstract translation: 结合人B细胞标记（称为CD20）的人源化，嵌合和人抗CD20抗体和CD20抗体融合蛋白，其可用于治疗和诊断B细胞病症，例如B细胞恶性肿瘤和自身免疫 疾病，治疗和诊断方法。 公开了制备人源化，嵌合抗体和人抗CD20抗体的方法。 公开了以高亲和力结合含有组胺 - 琥珀酰 - 甘氨酰（HSG）部分的分子结合的命名为h679的人源化抗HSG（组胺 - 琥珀酰 - 甘氨酰）单克隆抗体，以及制备人源化抗HSG抗体的方法。
-
4.发明授权公开(公告)号：US07534431B2
公开(公告)日：2009-05-19
申请号：US10768707
申请日：2004-02-02
Applicant: William J. McBride , Hans J. Hansen , Chien-Hsing Ken Chang , David M. Goldenberg
Inventor： William J. McBride , Hans J. Hansen , Chien-Hsing Ken Chang , David M. Goldenberg
IPC: A61K39/00 , A61K39/44 , A61K38/08 , A61K39/395 , A61K49/06 , A61K49/16 , C12P21/08 , C07K16/18 , C07K16/22 , C07K16/24
CPC classification number: B82Y5/00 , A61K47/6891 , Y10S435/975
Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
Abstract translation: 描述了使用靶向抗体或其他靶向动物将治疗和诊断分子靶向特定类型的细胞的方法和组合物。
-
公开(公告)号：US09745374B2
公开(公告)日：2017-08-29
申请号：US13402480
申请日：2012-02-22
Applicant: David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
Inventor： David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
CPC classification number: C07K16/2803 , A61K47/6817 , A61K47/6877 , C07K16/2833 , C07K2317/24 , C07K2317/41 , C07K2319/00 , C07K2319/33 , C12N9/22 , C12N2510/02
Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.
-
公开(公告)号：US08192739B2
公开(公告)日：2012-06-05
申请号：US12479250
申请日：2009-06-05
Applicant: David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
Inventor： David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
CPC classification number: C07K16/2803 , A61K47/6817 , A61K47/6877 , C07K16/2833 , C07K2317/24 , C07K2317/41 , C07K2319/00 , C07K2319/33 , C12N9/22 , C12N2510/02
Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.
Abstract translation: 可以在哺乳动物细胞培养物中产生含有与抗体或抗体片段融合的细胞毒性RNA的重组免疫毒素。 令人惊讶的是，可以制备含有与一个抗体可变结构域的N末端融合的细胞毒性RNA的免疫毒素，并保留特异性结合抗原的能力。 免疫毒素可以用于治疗与不想要的或不适当的细胞增殖或活化相关的疾病或综合征的各种治疗方法。
-
公开(公告)号：US07544487B2
公开(公告)日：2009-06-09
申请号：US11056182
申请日：2005-02-14
Applicant: David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
Inventor： David M. Goldenberg , Hans J. Hansen , Chien-Hsing Ken Chang , Sailaja S. Vanama , Edmund A. Rossi
CPC classification number: C07K16/2803 , A61K47/6817 , A61K47/6877 , C07K16/2833 , C07K2317/24 , C07K2317/41 , C07K2319/00 , C07K2319/33 , C12N9/22 , C12N2510/02
Abstract: Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.
Abstract translation: 可以在哺乳动物细胞培养物中产生含有与抗体或抗体片段融合的细胞毒性RNA的重组免疫毒素。 令人惊讶的是，可以制备含有与一个抗体可变结构域的N末端融合的细胞毒性RNA的免疫毒素，并保留特异性结合抗原的能力。 免疫毒素可以用于治疗与不想要的或不适当的细胞增殖或活化相关的疾病或综合征的各种治疗方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.023 seconds)
